To study the effectiveness of dipyridamole and low-dose aspirin, taken alone or in combination, for secondary stroke prevention.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Randomized, double-blind, placebo-controlled, trial of 6602 patients at 59 centers.
Patients were randomized to participate in 1 of 4 groups. 1) aspirin (25 mg twice daily) 2) modified-release dipyridamole (200 mg twice daily) 3) aspirin (25 mg twice daily) and modified-release dipyridamole (200 mg twice daily) 4) placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Stroke, death, and stroke and/or death as determined in follow-up visits 1 month after inclusion and thereafter, every 3 months for 2 years.|
|Secondary||TIA, myocardial infarction, ischemic events and other vascular events.|